The global coronary heart disease diagnostic imaging device market size is expected to reach USD 2.96 billion by 2030, registering a CAGR of 6.6% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increase in coronary diseases and deaths associated with it calls for better and early diagnosis of the condition. Precise scan interpretation and technologically advanced equipment are the factors influencing the market growth. Various imaging modalities are useful in identifying unique aspects of coronary screening. For instance, intravascular ultrasound, X-ray angiography, and computed tomography angiography (CTCA) provide a direct evaluation and quantification of alterations in the coronary arteries. However, non-invasive techniques like single-photon computed tomography (SPECT) and positron emission tomography (PET) provide indirect information on CHD by estimating the myocardial perfusion and metabolism abnormalities that are consequent of coronary artery disease.
Technological advancement in this field had led to the development of sharp camera units consisting of gamma systems, that use semiconductor detectors of cadmium zinc telluride (CZT). This led to faster acquisition of images, reduced capture time, high image quality, and lower radiation dose (1mSv for a single injection), as compared to conventional myocardial perfusion imaging by SPECT. Further, improvements around Computed Tomography, to develop non-invasive techniques have also shown great future growth in this segment. However, economic barriers, subject literacy, and lack of medical staff hold back the implementation of such advanced techniques in real practice.
The coronary heart disease diagnostic imaging devices market saw a sharp decline in 2020, due to the outbreak of the COVID-19 pandemic. Fear of virus spread, the shift in focus on diagnosing and treating COVID-19 affected patients, reduced admission rates at hospitals for other diseases, and reduced medical staff, led to the reduction in the diagnosis of CVD. Economic setback observed by end-users also influenced the adoption of advanced techniques to effectively diagnoses coronary alterations. Further, the shutting down of manufacturing units, due to national lockdowns, halt in logistics, and reduction in salesforce also impacted the market negatively.
Request a free sample copy or view report summary: Coronary Heart Disease Diagnostic Imaging Devices Market Report
Nuclear medicine dominated the modality segment due to the ease of image interpretation and accuracy in detection.
Computed tomography is anticipated to experience at the fastest CAGR o vefr the forecast period, due to its advantages of early detection of even the most intricate alterations which otherwise is impossible to det4ect in the traditional SPECT technology.
Asia Pacific is anticipated to be growing at a significant CAGR over the forecast period owing to the increase in R&D activities and numerous resellers.
Grand View Research has segmented the global coronary heart disease diagnostic imaging device market based on modality, and region:
Coronary Heart Disease Diagnostic Imaging Device Modality Outlook (Revenue, USD Million, 2018 - 2030)
Computed Tomography
X rays
Ultrasound
Magnetic Resonance Imaging
Nuclear Medicine
Coronary Heart Disease Diagnostic Imaging Device Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Coronary Heart Disease Diagnostic Imaging Device Market
Canon
Esaote SPA
FUJIFILM Holdings Corporation
GE Healthcare
Hitachi Medical Corporation
Koninkilijhe Phillips N.V.
SAMSUNG
Siemens Healthineers AG
Ziehm Imaging GmbH
"The quality of research they have done for us has been excellent..."